- 17Volume 4, 2021Jun 02, Issue 11May 19, Issue 10May 04, Issue 9Apr 20, Issue 8Apr 06, Issue 7Mar 23, Issue 6Mar 09, Issue 5Feb 23, Issue 4Feb 09, Issue 3Jan 26, Issue 2
- 16Volume 3, 2020Dec 15, Issue 25Dec 01, Issue 24Nov 17, Issue 23Oct 06, Issue 20Sep 08, Issue 18Aug 25, Issue 17Jul 14, Issue 14Jun 30, Issue 13Jun 16, Issue 12Jun 02, Issue 11May 19, Issue 10May 05, Issue 9Mar 10, Issue 5Feb 25, Issue 4Feb 04, Issue 3Jan 21, Issue 2Jan 07, Issue 01
- 15Volume 2, 2019Dec 17, Issue 22Nov 12, Issue 20Oct 28, Issue 19Oct 15, Issue 18Sep 03, Issue 15Aug 21, Issue 14Aug 05, Issue 13Jul 22, Issue 12Jul 08, Issue 11Jun 03, Issue 9May 13, Issue 8Apr 22, Issue 7Mar 11, Issue 4Feb 04, Issue 2Jan 21, Issue 1
- 14Volume 1, 2018Dec 21, Issue 12Dec 03, Issue 11Nov 19, Issue 10Nov 05, Issue 9Oct 22, Issue 8Oct 09, Issue 7Sep 24, Issue 6Sep 10, Issue 5Aug 15, Issue 4Jul 15, Issue 3Jul 01, Issue 1
Agenus on Twitter
$AGEN listed as one of biggest #ASCO21 risers in @evaluatevantage stock round-up. Agenus presented on differentiated activity of anti-PD-1 antibody balstilimab & new clinical data on AGEN2373, a CD137 agonist antibody evaluate.com/vantage/articl…
Agenus at #ASCO21 Agenus’ CMO @ODayMD offers his thoughts on Agenus' #AI VISION platform and AGEN2373 data presented @ASCO. Click to read more: investor.agenusbio.com/news-releases/…
Agenus’ Presentations at #ASCO21 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373 Bal demonstrates superior tumor killing potential in a VISION study. AGEN2373 shows no liver toxicity; combo trials are planned investor.agenusbio.com/news-releases/…
Agenus' collaboration with @bmsnews will allow us to accelerate the advancement of our differentiated pipeline while also giving us greater optionality as we pursue the best development strategy for each individual asset. investor.agenusbio.com/news-releases/…
Agenus newsletter now available: Setting the Stage for Innovation with Our Own PD-1 Having a PD-1 is critical to our I-O strategy. It provides commercial flexibility & opportunities to advance this agent for strategic combinations Click to read: agenusbio.com/agenusnews-vol…
Agenus to Participate in Fireside Chat at the @Jefferies 2021 Virtual Healthcare Conference Agenus' President and COO @jbuell01 will participate in a fireside chat on Friday, June 4, 2021 from 10:30am - 10:55am ET investor.agenusbio.com/news-releases/…
May is #NationalCancerResearchMonth, and we’re highlighting the incredible work our scientists do advancing #immunotherapy #NCRM21 #researchsaveslives
Listen to the latest @BioCentury podcast episode to hear about Agenus’ collaboration with @bmsnews and AGEN1777’s bispecific and Fc-enhanced design #TIGIT #oncology #Immunotherapy biocentury.com/article/636637…
REMINDER 🧬 @BiotechCH “Biotech Clubhouse: Sunday Hangout” - reviewing news of the week w/ me, @bradloncar, & @daphnezohar Join us tomorrow Sun May 23 at 4:00pm EDT w/ special guest @Agenus_Bio President/COO @jbuell01 to discuss their @bmsnews TIGIT deal! joinclubhouse.com/event/PAAjr28O Retweeted by Agenus Inc. ($AGEN)
Like the rest of Agenus' differentiated pipeline, AGEN1777 is optimally designed to address an unmet need. rb.gy/dpntx4
We are proud to collaborate with industry leader @bmsnews to develop this Fc enhanced anti-TIGIT bispecific while continuing to advance our other innovations like our Fc enhanced anti-CTLA-4 AGEN1181 to serve patients with cancer and disrupt the IO space #immunotherapy #TIGIT
@bmsnews makes potential $1.56 billion commitment to Agenus' antibody program #biotechnology #antibodies #pharmaceutical hubs.li/H0NzV7q0 Retweeted by Agenus Inc. ($AGEN)
Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target biopharmadive.com/news/bristol-m… by @NedPagliarulo $BMY $AGEN Retweeted by Agenus Inc. ($AGEN)
A Lexington biotech firm has signed its largest licensing deal ever for a tumor-fighting antibody that is still in preclinical development. bizjournals.com/boston/news/20… Retweeted by Agenus Inc. ($AGEN)
BMS to pay up to $1.56bn for Agenus’ bispecific antibody programme feedproxy.google.com/~r/Pharmatimes… #pharmanews #lifesciences Retweeted by Agenus Inc. ($AGEN)
Bristol Myers Squibb buys rights to Agenus's anti-TIGIT candidate in $1.56 billion deal @bmsnews @Agenus_Bio #Immunotherapy bit.ly/3bH0TsO Retweeted by Agenus Inc. ($AGEN)
Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts Balstilimab shows a differentiated profile both clinically and preclinically. AGEN2373 has been well tolerated in a dose escalation trial with no liver toxicity observed investor.agenusbio.com/news-releases/…
.@bmsnews is paying $200M for global rights to an @Agenus_Bio bispecific antibody that preclinical research shows has potential to best rest of the class. If it reaches the market, $AGEN could earn up to $1.36B in milestones, via @frankvinluan medcitynews.com/2021/05/bristo… $BMY #cancer Retweeted by Agenus Inc. ($AGEN)
TIGIT fidgets lessen as Agenus’ mystery preclinical bispecific bags BMS pact worth up to $1.3B-plus… bioworld.com/articles/50720… Retweeted by Agenus Inc. ($AGEN)
Bristol Pays Out $200m For Agenus' Preclinical Bispecific TIGIT bit.ly/3bAGXb8 #PharmaScrip Retweeted by Agenus Inc. ($AGEN)